These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16314887)

  • 1. The expanding role of BDNF: a therapeutic target for Alzheimer's disease?
    Fumagalli F; Racagni G; Riva MA
    Pharmacogenomics J; 2006; 6(1):8-15. PubMed ID: 16314887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease.
    Peng S; Wuu J; Mufson EJ; Fahnestock M
    J Neurochem; 2005 Jun; 93(6):1412-21. PubMed ID: 15935057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.
    Fumagalli F; Racagni G; Riva MA
    Pharmacogenomics J; 2006; 6(2):95-104. PubMed ID: 16402079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Ann N Y Acad Sci; 2007 Dec; 1122():155-68. PubMed ID: 18077571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies.
    Kozisek ME; Middlemas D; Bylund DB
    Pharmacol Ther; 2008 Jan; 117(1):30-51. PubMed ID: 17949819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy.
    Kuipers SD; Bramham CR
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):580-6. PubMed ID: 17002218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression.
    Borroni B; Archetti S; Costanzi C; Grassi M; Ferrari M; Radeghieri A; Caimi L; Caltagirone C; Di Luca M; Padovani A;
    Neurobiol Aging; 2009 Sep; 30(9):1406-12. PubMed ID: 18179845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depression and Alzheimer's disease: neurobiological links and common pharmacological targets.
    Caraci F; Copani A; Nicoletti F; Drago F
    Eur J Pharmacol; 2010 Jan; 626(1):64-71. PubMed ID: 19837057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying therapies in Alzheimer's disease.
    Salloway S; Mintzer J; Weiner MF; Cummings JL
    Alzheimers Dement; 2008 Mar; 4(2):65-79. PubMed ID: 18631951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the brain-derived neurotrophic factor and the apolipoprotein E polymorphisms on disease progression in preclinical Alzheimer's disease.
    Hashimoto R; Hirata Y; Asada T; Yamashita F; Nemoto K; Mori T; Moriguchi Y; Kunugi H; Arima K; Ohnishi T
    Genes Brain Behav; 2009 Feb; 8(1):43-52. PubMed ID: 18786162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
    Tsai SJ
    Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function.
    Teixeira AL; Barbosa IG; Diniz BS; Kummer A
    Biomark Med; 2010 Dec; 4(6):871-87. PubMed ID: 21133708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Possible relation of BDNF and GDNF to neuropsychiatric disorders].
    Hibi Y; Nitta A; Nabeshima T; Yamada K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Apr; 29(2):85-9. PubMed ID: 19562947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease.
    Zhang HY; Tang XC
    Trends Pharmacol Sci; 2006 Dec; 27(12):619-25. PubMed ID: 17056129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic intervention in dementia.
    Davis RE; Emmerling MR; Jaen JC; Moos WH; Spiegel K
    Crit Rev Neurobiol; 1993; 7(1):41-83. PubMed ID: 8096799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does neurotropin-3 have a therapeutic implication in major depression?
    Pae CU; Marks DM; Han C; Patkar AA; Steffens D
    Int J Neurosci; 2008 Nov; 118(11):1515-22. PubMed ID: 18853330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Born to Protect: Leveraging BDNF Against Cognitive Deficit in Alzheimer's Disease.
    Caffino L; Mottarlini F; Fumagalli F
    CNS Drugs; 2020 Mar; 34(3):281-297. PubMed ID: 32052374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls.
    Laske C; Stransky E; Leyhe T; Eschweiler GW; Maetzler W; Wittorf A; Soekadar S; Richartz E; Koehler N; Bartels M; Buchkremer G; Schott K
    J Psychiatr Res; 2007 Aug; 41(5):387-94. PubMed ID: 16554070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.